Castle Biosciences (CSTL) - Stock Price & Dividends

Castle Biosciences Inc., a pioneering molecular diagnostics company, revolutionizes the way we diagnose and treat various life-altering conditions. By harnessing the power of genetic expression profiling, they provide cutting-edge testing solutions for dermatologic cancers, Barrett's esophagus, uveal melanoma, and mental health conditions.

Their innovative portfolio includes DecisionDx-Melanoma, a game-changing risk stratification test that identifies the likelihood of metastasis in patients with invasive cutaneous melanoma. Additionally, they offer DecisionDx-SCC, a proprietary test that assesses the risk of metastasis in patients with cutaneous squamous cell carcinoma. MyPath Melanoma, another groundbreaking test, helps diagnose melanocytic lesions that are difficult to diagnose.

Their Barrett's esophagus testing solutions are equally impressive. TissueCypher, a spatial omics test, predicts the future development of high-grade dysplasia and/or esophageal cancer in patients with non-dysplastic, indefinite dysplasia, or low-grade dysplasia Barrett's esophagus. This empowers healthcare professionals to take proactive measures, improving patient outcomes.

Furthermore, Castle Biosciences offers DecisionDx-UM, a proprietary test that predicts the risk of metastasis in patients with uveal melanoma. IDgenetix, their pharmacogenomic test, helps guide personalized drug treatment for various mental health conditions, including major depressive disorder, schizophrenia, bipolar disorder, anxiety disorders, social phobia, obsessive-compulsive personality disorder, post-traumatic stress disorder, and attention deficit hyperactivity disorder.

By targeting skin cancer, gastroenterology, and mental health markets, Castle Biosciences is dedicated to improving patient care and outcomes. Founded in 2007, the company is headquartered in Friendswood, Texas, and continues to push the boundaries of molecular diagnostics. Learn more about their innovative solutions at https://castlebiosciences.com.